Answers are grounded in this paper and cite their sources.
Elexacaftor-tezacaftor-ivacaftor was efficacious in patients with cystic fibrosis with Phe508del-minimal function genotypes, in whom previous CFTR modulator regimens were ineffective. (Funded by Vertex Pharmaceuticals; VX17-445-102 ClinicalTrials.gov number, NCT03525444.).
No takes yet. Share an insight, caveat, or question.
Middleton et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: